- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Mentor Announces Collaboration Agreement With Valeant Pharmaceuticals
New physician loyalty program offers broad portfolio of aesthetic products
CHMP Gives A Positive Opinion For The Use Of VELCADE® As Retreatment And For Frontline Induction Therapy Before Stem Cell Transplantation
Label updates could lead to significantly improved outcomes for patients with multiple myeloma
Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes
Phase 3 Results for INVOKANA™ Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure
Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of Medicine
A second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition
Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition
Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting
Late-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations